Navigation Links
Teva Applauds Historic Biotech Competition Legislation
Date:3/11/2009

Bi-Partisan Waxman-Deal Bill will increase access and savings for American consumers

NORTH WALES, Pa., March 11 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today applauded the introduction of a landmark, bi-partisan bill that would bring safe and affordable generic biologics to all Americans. Energy and Commerce Chairman Henry Waxman and Ranking Health Subcommittee Republican Nathan Deal, together with Representatives Frank Pallone and Jo Ann Emerson, introduced the Promoting Innovation and Access to Life Saving Medicines Act in the House of Representatives today following years of debate over the establishment of an FDA approval pathway for biogenerics.

"Representatives Waxman, Deal, Pallone and Emerson have reached a remarkable milestone with this bill; one that can have an enormous positive impact on our biopharmaceutical market," said William Marth, President and CEO of Teva North America. "But more importantly, it's a law that can provide a vast benefit for all Americans and save billions at the same time. Teva looks forward to working with Congress, the White House and stakeholders nationwide to see their work become a reality," Marth concluded.

The average daily cost of a biologic product is approximately 22 times greater than a traditional drug. The potential savings from biogenerics are huge. A 2008 economic study found that a U.S. biogenerics market would both promote competition and generate cost savings of just over $100 billion over the next 10 years. Large employers, pharmacy benefits managers, health plans, consumer groups, generic drug manufactures and others have been waiting for legislation that will establish a sound scientific regulatory pathway and properly balance the need for patient access with incentives for continued innovation.

Just last month, Teva launched the "Year of Affordable Healthcare," a nationwide campaign to recognize the important role that generic drugs play and commemorate the 25th anniversary of the landmark Waxman-Hatch Act which created the modern generic drugs industry and has resulted in billions of dollars of savings.

About Teva

Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., one of the largest generic pharmaceutical companies in the world and among the top 20 pharmaceutical companies. For more information, please visit www.tevausa.com or www.tevadc.com.


'/>"/>
SOURCE Teva Pharmaceuticals USA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. International Society for Stem Cell Research Applauds Outcome of Proposal 2 Advancing Stem Cell Research
2. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
3. Air Transport Association Applauds House of Representatives on Decision to Withhold Biometric Collection Funding
4. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
5. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
6. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
7. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
8. FRC Applauds New Ballot Initiative for Cures Without Cloning
9. Monsantos Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment
10. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
11. African Ancestry, Educators, Identity Experts Launch DNA Education Project during Historic Black History Month; 7th Graders Score High on Ultimate Self Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... , Dec. 8, 2016 Savannah ... remediation technologies and selected NewTechBio,s NT-MAX Lake ... microbial based beneficial bacteria, in conjunction with Hexa ... correct deficiencies with National Pollutant Discharge Elimination System ... has experienced a steady history of elevated pH ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman ... has become a Wonderware Certified System Integrator Partner. Huffman Engineering is the ... Software. , “The System Integrator Partner certification gives customers confidence that our engineers ...
Breaking Biology Technology:
(Date:12/8/2016)... -- Market Research Future published a half cooked research report on ... and Service Market is expected to grow over the CAGR of ... ... Mobile Biometric Security and Service Market is increasing ... authentication and security from unwanted cyber threats. The increasing use of ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
Breaking Biology News(10 mins):